Rational 'DOTS Plus' for the control of MDR-TB

International Journal of Tuberculosis and Lung Disease

Volumn 3, Issue 7, 1999, Pages 561-563

  Espinal, M A ^a   Dye, C ^a   Raviglione, M ^a   Kochi, A ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE PREDISPOSITION; HEALTH PROGRAM; INDIVIDUALIZATION; INFECTION CONTROL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; COMMUNICABLE DISEASE CONTROL; HUMANS; MICROBIAL SENSITIVITY TESTS; PRACTICE GUIDELINES; SWITZERLAND; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

EID: 0032771965     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Farmer P, Bayona J, Becerra M, et al. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis 1998; 2: 869-876.
2. China Tuberculosis Control Collaboration. Results of directly observed short course chemotherapy in 112 842 Chinese patients with smear-positive tuberculosis. Lancet 1996; 347: 358-362.
3. Tuberculosis control in high-prevalence countries: the Tanzania experience. In: Davies P D O, ed. Clinical Tuberculosis. 1994: 335-339.
4. Tanzania National Tuberculosis and Leprosy Programme: Summary Reports. Dar es Salaam: Ministry of Health; 1991-1995.
5. Ministerio de Salud del Peru. Evaluacion operacional del Programa Nacional de Control de Tuberculosis en el Perú y cumplimiento de las metas de gestion para el ano 1997. Lima, Peru: National TB Control Programme 1998.
6. Valenzuela M T, Garcia P, Ponce J, Lepe R, Velasco M, Piffardi S. Drug resistance of M. tuberculosis in Chile: rates of initial resistance for 1986 and acquired resistance for 1985. Bull Int Union Tuberc Lung Dis 1989; 64: 13-14.
7. WHO/IUATLD. Anti-Tuberculosis Drug Resistance in the World. WHO/TB/97.229. Geneva, Switzerland: World Health Organization 1997.
8. Coates A R M, Mitchison D A. The role of sensitivity tests in short-course chemotherapy. Bull Int Union Tuberc 1983; 58: 110-114.
9. Mitchison D A, Nunn A J. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-430.
10. Hong Y P, Kim S J, Lew W J, Lee E K, Han Y C. The seventh nationwide tuberculosis prevalence survey in Korea, 1995. Int J Tuberc Lung Dis 1998; 2: 27-36.
11. Kim S J, Bai S H, Hong Y P. Drug-resistant tuberculosis in Korea. Int J Tuberc Lung Dis 1997; 1: 302-308.
12. WHO/IUATLD. Use of a standard third-line treatment regimen for tuberculosis patient failing treatment on a standard rifampicin-throughout regimen: generic guidelines for protocol development. Unpublished WHO document.
13. Crofton J, Chaulet P, Maher, D. Guidelines for the management of drug-resistant tuberculosis. WHO/TB/96.210. Geneva, Switzerland: World Health Organization 1997.
14. Farmer P, Kim J Y. Community-based approaches to the control of multidrug-resistant tuberculosis: introducing "DOTS-PLUS". Brit Med J 1998; 317: 671-674.
15. WHO/IUATLD Working Group on Antituberculosis Drug Resistance Surveillance. Guidelines for surveillance of drug resistance in tuberculosis. WHO/TB/96.216. Geneva, Switzerland: World Health Organization, 1997.
16. Uplekar M W, Rangan S. Private doctors and tuberculosis control in India. Tubercle Lung Dis 1993; 74: 332-337.
17. Pablos-Mendez A, Raviglione M C, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. N Engl J Med 1998; 338: 1641-1649.
18. Iseman M. MDR-TB and the developing world - a problem no longer to be ignored: the WHO announces the 'DOTS Plus' strategy. Int J Tuberc Lung Dis 1998; 2: 867.